<DOC>
	<DOCNO>NCT00383448</DOCNO>
	<brief_summary>Hematopoietic stem cell transplantation proven effective therapy individual adrenoleukodystrophy ( ALD ) , metachromatic leukodystrophy ( MLD ) globoid cell leukodystrophy ( GLD , Krabbe disease ) . This protocol also consider inherited metabolic disease , limit , GM1 gangliosidosis , Tay Sachs disease , Sanfilippo syndrome Sandhoff disease , I-cell disease ( mucolipidosis II ) . For patient advance rapidly progressive disease , morbidity mortality transplantation unacceptably high . Unfortunately , viable alternative therapeutic option patient ; transplantation perform patient send home die . Our group Minnesota develop new protocol incorporate transplantation use reduce intensity condition regimen design decrease toxicity associate transplant procedure . This regimen make use drug clofarabine , lympholytic immune suppressive property without neurologic toxicity observe related compound , fludarabine , commonly use transplantation . In addition , several agent provide anti-oxidant anti-inflammatory property use assist stabilization disease process . This revise transplant protocol test following : 1 ) ability achieve engraftment reduce intensity protocol , 2 ) mortality associate transplant day 100 , 3 ) patient outcome , base differential neurologic , neuropsychologic , image biologic evaluation prior transplantation designate point transplantation ( day 100 , 6 month , 1 , 2 5 year ) . Additional biologic study include pharmacokinetics clofarabine mycophenolate mofetil ( MMF ) . In addition , patient undergo lumbar puncture study , cerebrospinal fluid ( CSF ) request determination biologic parameter .</brief_summary>
	<brief_title>HSCT High Risk Inherited Inborn Errors</brief_title>
	<detailed_description>Hematopoietic stem cell transplantation proven effective therapy individual adrenoleukodystrophy ( ALD ) , metachromatic leukodystrophy ( MLD ) globoid cell leukodystrophy ( GLD , Krabbe disease ) . However , patient advance rapidly progressive disease , morbidity mortality transplantation unacceptably high . Unfortunately , viable alternative therapeutic option patient ; transplantation perform patient send home die . Our group Minnesota develop new protocol incorporate transplantation use reduce intensity condition regimen design decrease toxicity associate transplant procedure . This regimen make use drug clofarabine , lympholytic immune suppressive property without neurologic toxicity observe related compound , fludarabine , commonly use transplantation . In addition , several agent provide anti-oxidant anti-inflammatory property use assist stabilization disease process . This revise transplant protocol test following : 1 ) ability achieve engraftment reduce intensity protocol , 2 ) mortality associate transplant day 100 , 3 ) patient outcome , base differential neurologic , neuropsychologic , image biologic evaluation prior transplantation designate point transplantation ( day 100 , 6 month , 1 , 2 5 year ) . Additional biologic study include pharmacokinetics clofarabine mycophenolate mofetil ( MMF ) , develop experience kinetics N-acetylcysteine , evaluate biologic marker oxidative status transplantation . In addition , patient undergo lumbar puncture study , cerebrospinal fluid ( CSF ) request determination biologic parameter .</detailed_description>
	<mesh_term>Adrenoleukodystrophy</mesh_term>
	<mesh_term>Gangliosidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis III</mesh_term>
	<mesh_term>Tay-Sachs Disease</mesh_term>
	<mesh_term>Wolman Disease</mesh_term>
	<mesh_term>Leukodystrophy , Metachromatic</mesh_term>
	<mesh_term>Leukodystrophy , Globoid Cell</mesh_term>
	<mesh_term>Sandhoff Disease</mesh_term>
	<mesh_term>Gangliosidosis , GM1</mesh_term>
	<mesh_term>Mucolipidoses</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>Adrenoleukodystrophy : Patients 055 year age diagnose ALD determine long chain fatty acid test eligible protocol evidence cerebral cerebellar disease base MRI testing , AND determine high risk follow reason : 1 . Age &gt; 18 year 2 . MRI score &gt; 10 3 . Evidence aggressive disease judgment Inherited Metabolic Storage Disease group sufficiently concern consider transplantation reduce intensity regimen instead standard full preparative regimen . Metachromatic Leukodystrophy : Patients 055 year age diagnose MLD determine determination arylsulfatase A test eligible protocol IF determine high risk follow reason : 1 . Age &gt; 18 year 2 . Symptomatic disease , base neurologic examination , evidence deterioration base subsequent neuropsychologic evaluation . 3 . Evidence aggressive disease rapidly change MRI determination judgment Inherited Metabolic Storage Disease group sufficiently concern consider transplantation reduce intensity regimen instead standard full preparative regimen . Globoid Cell Leukodystrophy : Patients 055 year age diagnose GLD determine determination galactocerebrosidase test eligible protocol IF determine high risk follow reason : 1 . Age &gt; 18 year 2 . Symptomatic disease , base neurologic examination , evidence deterioration base subsequent neuropsychologic evaluation . 3 . Evidence aggressive disease rapidly change MRI determination judgment Inherited Metabolic Storage Disease group sufficiently concern consider transplantation reduce intensity regimen instead standard full preparative regimen . Patients GM1 gangliosidosis , Tay Sachs disease , Sanfilippo syndrome , Wolman disease Sandhoff disease inherit metabolic disease include limited Icell disease ( mucolipidosis II ) determine sufficiently advance high risk base follow reason : 1 . Symptomatic disease , base neurologic examination , evidence deterioration base subsequent neuropsychologic evaluation . 2 . Evidence expect poor outcome base genetic test prior family history aggressive disease . 3 . Other metabolic disorder , include limit Icell disease , deem highrisk poor outcome standard transplant regimen due anticipate toxicity base experience gain University Minnesota center . Exclusion criterion : Major organ dysfunction . Advanced Disease Exclusion : Following evaluation , consensus member Inherited Metabolic Storage Disease Program patient advance benefit measurable meaningful way transplant , communicate family , transplant offer . Measures assist determination may include : neurologic/neurocognitive function activity daily live , motor function , vision , hearing , interaction environment , toileting , swallow , standardized measure</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Stem cell transplantation</keyword>
	<keyword>Inborn error metabolism</keyword>
	<keyword>Adrenoleukodystrophy ( ALD )</keyword>
	<keyword>Metachromatic leukodystrophy ( MLD )</keyword>
	<keyword>Globoid cell leukodystrophy ( GLD Krabbe )</keyword>
	<keyword>Tay Sachs</keyword>
	<keyword>Sandhoff</keyword>
	<keyword>Sanfilippo syndrome</keyword>
	<keyword>Mucopolysaccharidosis III ( MPS-III )</keyword>
	<keyword>GM1 gangliosidosis</keyword>
	<keyword>I-cell</keyword>
	<keyword>mucolipidosis</keyword>
</DOC>